267 related articles for article (PubMed ID: 26633622)
21. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
22. Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis.
Carvalho PD; Duarte C; Vieira-Sousa E; Cunha-Miranda L; Avila-Ribeiro P; Santos H; Bernardes M; Santos MJ; Cerqueira M; Mateus M; Nero P; Águeda A; Silva JA; Machado P
Acta Reumatol Port; 2017; 42(1):55-65. PubMed ID: 27750274
[TBL] [Abstract][Full Text] [Related]
23. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
24. Can biologic therapies be withdrawn or tapered in psoriatic arthritis?
Moverley AR; Coates LC; Helliwell PS
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S51-3. PubMed ID: 24129138
[TBL] [Abstract][Full Text] [Related]
25. A review on golimumab in the treatment of psoriatic arthritis.
Urdaneta M; Jethwa H; Sultan R; Abraham S
Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
Kristensen LE; Lie E; Jacobsson LT; Christensen R; Mease PJ; Bliddal H; Geborek P
J Rheumatol; 2016 Jan; 43(1):81-7. PubMed ID: 26628604
[TBL] [Abstract][Full Text] [Related]
27. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
28. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.
Greenberg JD; Palmer JB; Li Y; Herrera V; Tsang Y; Liao M
J Rheumatol; 2016 Jan; 43(1):88-96. PubMed ID: 26628601
[TBL] [Abstract][Full Text] [Related]
29. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
30. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy?
Bruzzese V; Marrese C; Scolieri P; Hassan C; Lorenzetti R; Zullo A
Int J Rheum Dis; 2015 Mar; 18(3):375-6. PubMed ID: 24702703
[No Abstract] [Full Text] [Related]
31. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
[TBL] [Abstract][Full Text] [Related]
32. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
[TBL] [Abstract][Full Text] [Related]
33. Regional review of patients with psoriatic arthritis in secondary care in the West Midlands: prevalence, disease activity and eligibility for anti-tumour necrosis factor therapy.
Bateman J; Cardy CM; Khan SY; Menon A; Obrenovic K; Rowe IF; Erb N
Clin Exp Rheumatol; 2009; 27(6):935-9. PubMed ID: 20149308
[TBL] [Abstract][Full Text] [Related]
34. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.
Köhm M; Burkhardt H; Behrens F
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S109-14. PubMed ID: 26472504
[TBL] [Abstract][Full Text] [Related]
35. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors.
Tsuruta N; Narisawa Y; Imafuku S; Ito K; Yamaguchi K; Miyagi T; Takahashi K; Fukamatsu H; Morizane S; Koketsu H; Yamaguchi M; Hino R; Nakamura M; Ohyama B; Ohata C; Kuwashiro M; Sato T; Saito K; Kaneko S; Yonekura K; Hayashi H; Yanase T; Morimoto K; Sugita K; Yanagihara S; Kikuchi S; Mitoma C; Nakahara T; Furue M; Okazaki F
J Dermatol; 2019 Mar; 46(3):193-198. PubMed ID: 30628100
[TBL] [Abstract][Full Text] [Related]
36. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
[TBL] [Abstract][Full Text] [Related]
37. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
38. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
39. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.
Diamantopoulos A; Benucci M; Capri S; Berger W; Wintfeld N; Giuliani G; Ricciardi W
J Med Econ; 2012; 15(3):576-85. PubMed ID: 22313326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]